|
private:ruiyibio-2
|
3615267
|
Dec 3rd, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Dec 3rd, 2020 12:46PM
|
Dec 3rd, 2020 12:46PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Dec 2nd, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Dec 2nd, 2020 04:05PM
|
Dec 2nd, 2020 04:05PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Dec 1st, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Dec 1st, 2020 02:32PM
|
Dec 1st, 2020 02:32PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 30th, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Nov 29th, 2020 08:35PM
|
Nov 30th, 2020 03:23PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 28th, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Nov 28th, 2020 04:10PM
|
Nov 28th, 2020 04:10PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 27th, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Nov 27th, 2020 12:35PM
|
Nov 27th, 2020 12:35PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 26th, 2020 12:00AM
|
RuiYi, Inc.
|
181
|
18.00
|
Open
|
Research
|
Nov 25th, 2020 07:21PM
|
Nov 26th, 2020 01:34PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 24th, 2020 12:00AM
|
RuiYi, Inc.
|
182
|
18.00
|
Open
|
Research
|
Nov 24th, 2020 02:43PM
|
Nov 24th, 2020 02:43PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 23rd, 2020 12:00AM
|
RuiYi, Inc.
|
182
|
18.00
|
Open
|
Research
|
Nov 23rd, 2020 04:41PM
|
Nov 23rd, 2020 04:41PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|
|
private:ruiyibio-2
|
3615267
|
Nov 22nd, 2020 12:00AM
|
RuiYi, Inc.
|
182
|
9.00
|
Open
|
Research
|
Nov 22nd, 2020 03:38PM
|
Nov 22nd, 2020 03:38PM
|
RuiYi is focused on the discovery and development of novel antibodies with upsized potential that represent (1) first in class antibody therapeutics to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics to validated targets for unique markets, including emerging markets, with significant medical need. RuiYi is developing biologic therapeutics for rheumatoid arthritis, metabolic disease, fibrosis and NASH. RuiYi's novel antibody discovery platform (intramembranous Confirmation Antigen Presenting System or "iCAPS") was developed internally under the direction of scientific founder Ray Stevens.
|
|
|
Open
|
505 Coast Blvd South Ste 300
|
La Jolla
|
CA
|
US
|
92037
|
|
Ruiyibio
|
|
Pharmaceuticals & Biotechnology
|